Basic Information

Gene symbol TNFRSF17 Synonyms BCM, BCMA, CD269, TNFRSF13A Type of gene protein-coding
Description TNF receptor superfamily member 17

GTO ID GTC0364
Trial ID NCT03093168
Disease Multiple Myeloma
Altered gene BCMA
Therapeutic/Target gene Target gene
TherapyCAR-T cell
Treatment BCMA CAR-T cells
Generation2nd
PhasePhase1
Recruitment statusUnknown
TitleBCMA Chimeric Antigen Receptor Expressing T Cells in Multiple Myeloma
Year2017
CountryChina
Company sponsorThe Second Affiliated Hospital of Henan University of Traditional Chinese Medicine
Other ID(s)anti-BCMA CART
Vector information
Vectorretrovirus
ConstructscFv-4-1BB-CD3ζ
Vector typegammaretrovirus vector
Additional featuretEGFR

Clinical Result

Cohort1: MM
Administration route None
Dosage 9E6 cells/kg
Donor type Autologous
Pts 44
Age Adult, Older_Adult
Lymph depletion Yes
Outcome 18/44(CR); 16/44(PR). The medianPFS is 15mon, and the median OS result has not been reached (49.16% progression-free survival, and 53.95% overall survival at 24 months).
Adverse reactions 3/44(cytokine release syndrome)
References DOI: 10.1182/blood-2019-127608
Cohort2: Relapsed/Refractory MM_ECOG 0-2
Administration route None
Dosage 9E6 cells/kg
Donor type Autologous
Pts 29
Age Adult, Older_Adult
Lymph depletion Yes
Outcome 79.31%(ORR); 10/29(CR); 9/29(PR)
Adverse reactions 11/29(cytokine release syndrome)
References DOI: 10.1182/blood-2019-127608
Cohort3: Relapsed/Refractory MM_ECOG 3-4
Administration route None
Dosage 9E6 cells/kg
Donor type Autologous
Pts 20
Age Adult, Older_Adult
Lymph depletion Yes
Outcome 75.00%(ORR); 9/20(CR); 8/20(PR)
Adverse reactions 6/20(cytokine release syndrome)
References DOI: 10.1182/blood-2019-127608

Relationship Graph

Overview of Knowledge Graph